Abstract: A non-invasive system and method for disease detection and real-time monitoring of organ health wherein the changes in the electrical properties of urine samples are studied over time in the presence or absence of interacting chemicals for qualitative and quantitative estimation of urinary analytes. The system has two components—a test platform and a reader. The test platform is integrated with electrodes and chemicals, which interact with urine to detect the biomarker of the disease and quantify the analyte. The changes in the electrical properties serve as an electrical signature for a particular analyte. This electrical signal from the test platform is relayed to an electronic reader that receives, processes, and analyzes the data for single test detection or continuous monitoring. The reader stores the information that can then be coupled to a readout system or transmitted by wired or wireless mechanisms to any electronic platform in real-time.

Abstract: Affinity sensors may exhibit advantaged regeneration behavior when pH is changed in proximity to a sensing element. Such affinity sensors may comprise at least one sensing element comprising a recognition moiety that interacts with an analyte by reversibly forming an analyte complex, and a solid-state pH-modulating element in proximity to the at least one sensing element, wherein formation of the analyte complex is pH-dependent and the at least one sensing element provides a signal that changes when the analyte complex reversibly forms, and a change in magnitude of the signal is correlatable to an amount of analyte interacted with the at least one sensing element.

Abstract: A time-resolved fluorescence immunochromatographic kit for simultaneous detection of mixed contamination of five mycotoxins such as aflatoxin B1 and an application thereof are disclosed. The kit comprises a time-resolved fluorescent immunochromatographic test strip and sample reaction vials each containing a europium-labeled monoclonal antibody lyophilized product; wherein the fluorescent test strip comprises a PVC substrate, and a surface of the PVC substrate is adhered with a water absorbing pad (1), a detection pad (2) and a sample pad (3) from top to bottom, adjacent pads being connected and overlapping at connections. The detection pad (2) adopts a nitrocellulose membrane as the base thereof and is arranged with a lateral quality control line (5) and five detection lines (5, 6, 7, 8, 9) from top to bottom each covered by a bovine serum albumin conjugate of each toxin.

Abstract: The present invention provides microfluidic pScreen™ devices for quantifying the concentration of DNA fragments in a liquid sample by using magnetic-responsive silica micro-beads and nonmagnetic-responsive silica micro-beads. The devices of the present invention allow for rapid, simple and inexpensive quantification of DNA fragment concentration in a sample. The devices do not require complex instrumentation and can be performed in less than three minutes. Moreover, they are compatible with complex samples including, without limitation, unpurified PCR amplification products, and thus can be expected to seamlessly integrate into various common molecular biology techniques and workflows.

Abstract: A fluid test cartridge, a fluid test apparatus, and a method for controlling the same. The fluid test apparatus includes a housing, and a fluid test cartridge that is accommodated in the housing. The fluid test cartridge includes at least one chamber in which a fluid sample to be tested and a drying reagent can be accommodated. The fluid test apparatus includes a light emitter configured to emit light to the at least one chamber, a light sensor, and a processor configured to detect a concentration of a first material in the fluid sample. The drying reagent includes a non-metallic particle bound to a second material that specifically binds to the first material. Tests can thus be carried out over a wider range of wavelengths, and testing errors can be reduced.

Abstract: An object of the present invention is to provide a reagent kit, a measurement kit, and a measurement method for measuring serum amyloid A, which enable measurement having a high correlation of an increase in signal with respect to the concentration of serum amyloid A. According to the present invention, provided is a reagent kit for measuring serum amyloid A, including first particles having a label and modified with a first binding substance having a property of specifically binding to serum amyloid A, and at least one nonionic surfactant having an HLB value of 17 to 20, which is defined by (inorganicity value/organicity value)×10 and a molecular weight of 1000 or less.

Abstract: A device for detecting and/or quantifying functional C1-esterase inhibitor (fC1-INH), the device comprising: (i) a conjugate pad comprising a first zone and a second zone, on which a first agent and a second agent are immobilized, respectively, and (ii) a membrane, which is in communication with the conjugate pad, wherein the membrane comprises a third zone, on which a third agent is immobilized. The conjugate pad may further comprise a fourth zone for placing a biological sample, which flows through the device in the order of the first zone, the second zone, and the third zone.

Abstract: A method for activating and expanding isolated T cells, the method including adding to isolated T cells ligands presenting microbubbles having a flexible lipid shell with an inner bubble wall enclosing a gas and an outer bubble wall conjugated to ligands capable of achieving cell contact dependent juxtacrine signaling on the isolated T cells; and adding to isolated T cells ligands presenting microbubbles having a flexible lipid shell with an inner bubble wall enclosing a gas and an outer bubble wall conjugated to an antigen capable of forming an immunological synapse (IS) with the T cells.

Abstract: An optical biomodule for detecting a disease specific biomarker(s), utilizing enhanced fluorescence emission (due to integration of (three-dimensional (3-D) structures in a fluidic container) upon chemical binding/coupling of a disease specific biomarker(s) with its corresponding disease specific biomarker binder(s) is disclosed. The three-dimensional (3-D) structure(s) may be coupled with an optical resonator and/or a photonic crystal and/or a metamaterial and/or a metamaterial of Epsilon-Near-Zero (ENZ) of a suitable wavelength range. Furthermore, a laser source to induce fluorescence may include a quantum dot laser or Bose-Einstein condensate (BEC).

Abstract: A biosensor system package includes: a transistor structure in a semiconductor layer having a front side and a back side, the transistor structure comprising a channel region; a buried oxide (BOX) layer on the back side of the semiconductor layer, wherein the buried oxide layer has an opening on the back side of the channel region, and an interface layer covers the back side over the channel region; a multi-layer interconnect (MLI) structure on the front side of the semiconductor layer, the transistor structure being electrically connected to the MLI structure; and a cap structure attached to the buried oxide layer, the cap structure comprising a microneedle.

Abstract: A field effect transistor comprising a chelator or derivatized chelator, a device for detecting a marker in a sample comprising said sensor, a method for detecting metal ions in a sample comprising said sensor or device and a sensor and method for detecting a marker in a sample.

Abstract: The present disclosure relates to a method for detection of an antibody or antibody fragment in a biological sample from a subject. In some embodiments, the methods comprise immobilizing a first binding agent on a surface plasmon resonance (SPR) biosensor; adding a ligand that binds to the first binding agent under conditions such that a complex of the ligand and the first binding agent is formed; adding an aliquot of the biological sample under conditions such that the antibody and/or antibody fragment binds to the ligand that is complexed to the first binding agent; and detecting the presence of the antibody and/or antibody fragment as a change in signal obtained from SPR. In some embodiments, the antibody is an antibody therapeutic such as certolizumab pegol. Also disclosed are systems and kits for detecting an antibody in a biological sample from a subject using SPR.

Abstract: The present invention provides a method of quantitatively analyzing a target substance, the method including a step of irradiating a biochip, which includes a plurality of target substances excluding a fluorescence-labeled material, with light; a step of acquiring a plurality of low-resolution images for a region including the plurality of target substances using an image sensor; a step of acquiring a high-resolution image based on the plurality of low-resolution images; and a step of counting the plurality of target substances in the high-resolution image; and a device for quantitatively analyzing a target substance using the method.

Abstract: A method for discriminating between Parkinson's disease and multiple system atrophy, the method comprising the steps of: (1) preparing a solution containing ?-synuclein monomers having a tendency to produce rod-like aggregates and/or a solution containing ?-synuclein monomers having a tendency to produce twisted aggregates; (2) adding a biological sample from a subject to the solution(s) containing the ?-synuclein monomers prepared in step (1); (3) allowing the ?-synuclein monomers to aggregate in the solution(s) obtained in step (2); and (4) detecting ?-synuclein aggregates formed in step (3).

Abstract: An apparatus for detecting a biomarker includes a particulate capturing structure for receiving and capturing exhaled breath aerosol (EBA) particulate from airway linings of a user, the particulate capturing structure having an aerosol particulate testing system for receiving the captured particulate and detecting a first biomarker, wherein the aerosol particulate testing system includes a dissolvable EBA sample collector film for capturing EBA particulate. The apparatus may include a droplet harvesting structure for converting breath vapor to a fluid droplet for forming a fluid sample and a testing system having a biomarker testing zone for receiving the fluid sample and detecting a biomarker.

Abstract: A sensor for liquid biopsy, its method of making, and its method of non-invasive use. The sensor includes a substrate with a surface functionalized with biotinylated antibodies. The biotinylated antibodies are arranged to engage with surface proteins on exosomes associated with malignant cancer cells such as glioma cells.

Abstract: The present disclosure provides apparatuses and methods for analyzing the presence of charged analytes and/or the binding force between charged analytes and a capture probe. The apparatuses and methods of the present disclosure can be operated in a multiplexed format to perform various assays of clinical significance for example.

Abstract: A test strip with selective white blood cell (WBC) lysis for release of WBC contents and the capture and holding of red blood cells (RBC), allowing for fast clearance and result interpretation and more accurate results at early time points due to the lack of red color interference caused by background red heme color of lysing of RBCs. The removal of the red color interference enhances both visual and digital interpretation of test strips, such as test strips of an immunoassay test. The test strip enhances the detection of both intracellular proteins of WBCs and extracellular proteins of RBCs simultaneously such as MxA and CRP, MxA and PCT, MxA and HNL, and MxA and IL-6, MxA and myeloid cells (STREM-1), MxA and angiopoietin 2, MxA and vascular endothelial growth factor (VEGF) or its soluble vascular endothelial growth factor receptor-1 (sVEGFR1), MxA and heparin binding protein (HBP) or other combinations.

Abstract: The present invention provides, among other things, QMAX card based assays in different forms for various analytes, offering simpler, fast, more sensitive assaying.

Abstract: Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. The diagnostic devices may be used, for example, to identify the presence of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.